Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30509303 | 0.72 | NR3C2 (0.42) | CYP11B1CYP11B2MMP12NR3C2MAPT | |
| SCHEMBL13089619 | 0.72 | NR3C2 (0.45) | CYP11B1CYP11B2MMP12NR3C2PARP1 | |
| SCHEMBL19629973 | 0.72 | NR3C2 (0.42) | CYP11B1CYP11B2MMP12NR3C2PARP1 | |
| SCHEMBL1333452 | 0.72 | NR3C2 (0.42) | CYP11B1CYP11B2MMP12NR3C2MAPT | |
| SCHEMBL15979057 | 0.72 | NR3C2 (0.39) | CYP11B1CYP11B2MMP12NR3C2 | |
| SCHEMBL1332897 | 0.72 | NR3C2 (0.42) | CYP11B1CYP11B2MMP12NR3C2PARP1 | |
| SCHEMBL859012 | 0.72 | MMP12 (0.38) | CYP11B1CYP11B2MMP12NR3C2PARP1 | |
| SCHEMBL7958200 | 0.72 | MMP12 (0.38) | CYP11B1CYP11B2MMP12NR3C2PARP1 | |
| SCHEMBL10283759 | 0.72 | MMP12 (0.49) | CYP11B1CYP11B2MMP12NR3C2PARP1 | |
| SCHEMBL18307151 | 0.72 | MMP12 (0.38) | CYP11B1CYP11B2MMP12NR3C2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | EXELIXIS INC (US) | 2025-05-22 | — | — | US | claimed |
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | claimed |
| CN-110382505-B | Heterocyclic compounds useful as antibacterial agents and process for producing the same | 巴格沃克斯研究有限公司 | 2023-04-04 | — | — | CN | claimed |
| EP-3634968-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | BUGWORKS RES INC (US) | 2023-01-25 | — | — | EP | claimed |
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | EXELIXIS INC (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2025095272-A1 | NOVEL 6H-PYRIMIDO[5,4-B][1,4]OXAZINE-7(8H)-ONE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF | 한국과학기술연구원 | 2025-05-08 | — | — | WO | disclosed |
| WO-2025095272-A1 | NOVEL 6H-PYRIMIDO[5,4-B][1,4]OXAZINE-7(8H)-ONE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF | 한국과학기술연구원 | 2025-05-08 | — | — | WO | disclosed |
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | ZENTAUR THERAPEUTICS USA INC. | 2024-03-21 | — | — | US | disclosed |
| CN-117241801-A | Inhibition of ubiquitin-specific protease 1 (USP 1) | 福马治疗有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20230312474-A1 | PHENOL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230312474-A1 | PHENOL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-05 | — | — | US | disclosed |
| EP-3080115-B1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-05-08 | — | — | EP | disclosed |
| US-9868749-B2 | Fused imidazole and pyrazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-01-16 | — | — | US | disclosed |
| US-20160297837-A1 | Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity | EVOTEC (UK) LTD. (GB) | 2016-10-13 | — | — | US | disclosed |
| WO-2010055348-A1 | [4- (1-AMINO-ETHYL) -CYCLOHEXYL] -METHYL-AMINES AS ANTIBACTERIALS | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
| US-20100056502-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056502-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| WO-2008116815-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| EP-0228094-B1 | Pyrimido[5,4-b][1,4]oxazine derivatives, process for their preparation, medicament containing them and intermediate pyrimido[5,4-b][1,4]oxazine derivatives | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1991-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056502-A1 | COMPOUNDS | NRDC, NACA, NAA50 | CYP11B1 2194/4885CYP11B2 2152/4885MMP12 1258/4885 |
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | USP1, USP28, USP2 | CYP11B1 4076/4885CYP11B2 4410/4885MMP12 1152/4885 |
| US-20230312474-A1 | PHENOL DERIVATIVE | TYR, NCOR1, BET1 | CYP11B1 155/4885CYP11B2 92/4885MMP12 3588/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | CYP11B1 754/4885CYP11B2 977/4885MMP12 3294/4885 |
| US-20160297837-A1 | Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | CYP11B1 2131/4885CYP11B2 2400/4885MMP12 3176/4885 |
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | USP1, USP2, SUMO1 | CYP11B1 2603/4885CYP11B2 3255/4885MMP12 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.